Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: loss of sensation; Stomach pain; Lack of libido; Atrophy of vulva; Palpitations; Chest pain; This is a spontaneous report from a contactable consumer received from the Regulatory Agency. The regulatory authority report number is GB-MHRA-WEBCOVID-202106062104293270-6HRK8. An unspecified age female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Batch/Lot Number: FA1027), via an unspecified route of administration on an unspecified date as 1ST dose, Single Dose for COVID-19 immunisation. The patient''s medical history was not reported. The patient has not had symptoms associated with covid-19, has not had a covid-19 test, and is not enrolled in a clinical trial. Concomitant medications included chlorpheniramine maleate (BOOTS ALLERGY RELIEF ANTIHISTAMINE), ethinylestradiol, levonorgestrel (MAEXENI) taken from 01Jan2019, and paracetamol for unspecified indications (start and stop date were not reported). on an unspecified date the patient experienced loss of sensation. On 04Jun2021, the patient experienced stomach pain, lack of libido, atrophy of vulva, palpitations, and chest pain. The seriousness criteria of the events were considered to be other medically important condition. The patient reported that stomach pain and palpitations occurred during the night and caused her to wake up and intermittent dull chest pain followed on her right side. The patient also reported complete loss of sensation in clitoris. The outcome of the event loss of sensation was unknown. The outcome of the events palpitations, chest pain and stomach pain was on 05Jun2021. The outcome of the event lack of libido and atrophy of vulva was 06Jun2021. No follow-up attempts are possible. No further information is expected.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166